This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Melandri, G. Articles by Magnani, B. Search for Related Content PubMed PubMed Citation Articles by Melandri, G. Articles by Magnani, B.

Circulation, Vol 88, 2517-2523, Copyright © 1993 by American Heart Association

ARTICLES

Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial

G Melandri, F Semprini, V Cervi, N Candiotti, E Palazzini, A Branzi and B Magnani
Institute of Cardiology, University of Bologna, Italy.

BACKGROUND. Patients with chronic coronary artery disease exhibit a dysfunctioning endothelium, which may be responsible for exercise- induced platelet activation and expression of a procoagulant moiety. In this study, we evaluated the therapeutic efficacy of a low molecular weight heparin (Parnaparin) in patients with stable angina pectoris. METHODS AND RESULTS. According to a double-blind, randomized, placebo- controlled trial, 29 patients with stable exercise-induced angina pectoris and angiographically proven coronary artery disease received a single daily subcutaneous injection of Parnaparin or placebo on top of aspirin and conventional antianginal medication over 3 months. Patients randomized to Parnaparin showed a significant decrease in the fibrinogen level (P = .035) and an improvement in both the time to 1-mm ST segment depression (P = .008) and the peak ST segment depression (P = .015). The Canadian Cardiovascular Society class for angina pectoris was also improved by Parnaparin (P = .016). Parnaparin did not affect ADP and collagen-induced platelet aggregation, whereas thrombin-induced aggregation was reduced (P = .0001). The bleeding time was slightly prolonged, but this was not associated with any significant bleeding. CONCLUSIONS. Patients with stable angina pectoris may be treated with Parnaparin in addition to aspirin and conventional antianginal medication. Side effects are negligible, and compliance is excellent.

This article has been cited by other articles:

				M. Montebugnoli, S. Bugamelli, P. Calo, E. Zangheri, and P. Ferrari Prophylaxis of Venous Thromboembolism in Minor Orthopedic Surgery With Parnaparin Clinical and Applied Thrombosis/Hemostasis, July 1, 2007; 13(3): 249 - 258. [Abstract] [PDF]

				A. Gruber, U. M. Marzec, L. Bush, E. Di Cera, J. A. Fernandez, M. A. Berny, E. I. Tucker, O. J. T. McCarty, J. H. Griffin, and S. R. Hanson Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates Blood, April 1, 2007; 109(9): 3733 - 3740. [Abstract] [Full Text] [PDF]

				M. C. Kim, A. Kini, and S. K. Sharma Refractory angina pectoris: Mechanism and therapeutic options J. Am. Coll. Cardiol., March 20, 2002; 39(6): 923 - 934. [Abstract] [Full Text] [PDF]

				S. D. Fihn, S. V. Williams, J. Daley, and R. J. Gibbons Guidelines for the Management of Patients with Chronic Stable Angina: Treatment Ann Intern Med, October 16, 2001; 135(8_Part_1): 616 - 632. [Abstract] [Full Text] [PDF]

				K. M. English, R. P. Steeds, T. H. Jones, M. J. Diver, and K. S. Channer Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina : A Randomized, Double-Blind, Placebo-Controlled Study Circulation, October 17, 2000; 102(16): 1906 - 1911. [Abstract] [Full Text] [PDF]

				R. J. Gibbons, K. Chatterjee, J. Daley, J. S. Douglas, S. D. Fihn, J. M. Gardin, M. A. Grunwald, D. Levy, B. W. Lytle, R. A. O'Rourke, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina) J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2092 - 2197. [Full Text] [PDF]

				LOW-MOLECULAR-WEIGHT HEPARIN FOR STABLE ANGINA Journal Watch (General), January 11, 1994; 1994(111): 2 - 2. [Full Text]